COVID-19 Infection in Multiple Sclerosis Patients Treated with Rituximab Compared to Natalizumab and Healthy Controls: A Real-World Multicenter Study

Introduction: The impact of coronavirus disease 2019 (COVID-19) infection on patients with multiple sclerosis (MS) undergoing various immunomodulating therapies can vary. Individuals on B-cell therapy, such as rituximab, may be more susceptible to infection compared to those treated with natalizumab...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Thomas Mathew, Surabhi Garg, Saji K. John, Mal S. Kimi, Naom Z. Chhakchhuak, Sherina Koshy, Tenzin Yangdonq, Molly George, Shagun Bhardwaj, Yerasu M. Reddy, Uday Murgod, Vikram Kamath, Sonia Shivde, Sagar Badachi, Akshata Huddar, Gosala R. K. Sarma, Raghunandan Nadig
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wolters Kluwer Medknow Publications 2024-06-01
Colecção:	Annals of Indian Academy of Neurology
Assuntos:	covid-19 multiple sclerosis natalizumab rituximab
Acesso em linha:	https://journals.lww.com/10.4103/aian.aian_151_24
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!